Use of at least one micro(mi)RNA e.g. hsa-miR-126, hsa-miR-15b, hsa-miR-16, hsa-miR-17, hsa-miR-20a, and hsa-let7a, for the implementation of in vitro diagnosis method of gliomas

摘要

Use of at least one micro (mi)RNA comprising hsa-miR-126, hsa-miR-15b, hsa-miR-16, hsa-miR-17, hsa-miR-20a, hsa-let7a, hsa-let 7f, hsa-let 7d, hsa-miR-374, hsa-miR-409, hsa-miR-134, hsa-miR-339, hsa-miR-127, hsa-miR-151, hsa-miR-26b, hsa-miR-34b, hsa-miR-155, hsa-miR-210 or hsa-miR-10a, for the implementation of in vitro diagnosis method of gliomas, is claimed. Independent claims are included for: (1) a method for in vitro diagnosis of gliomas comprising: measuring the level of expression of (I) in a biological sample from a patient suspected of having glioma, comparing: between the level of expression of at least one the miRNA in the sample and the level of expression of the miRNAs in a healthy sample of reference or between the level of expression of at least one first of the miRNA in the sample obtained from a patient suspected of having a glioma and the level of expression of at least one second of the miRNAs in the same sample obtained from the patient suspected of having a glioma; (2) a kit for in vitro diagnosis of gliomas, comprising metering means of at least one miRNA comprising HSA-miR-126, hsa-miR-15b, hsa-miR-16, hsa-miR-17, hsa-miR-20a, hsa-let7a, hsa-let 7f, hsa-let 7d, hsa-miR-374, hsa-miR-409, hsa-miR-134, hsa-miR-339, hsa-miR-127, hsa-miR-151, hsa-miR-26b, hsa-miR-34b, hsa-miR- 155, hsa-miR-210 or hsa-miR-10a; and (3) a method of evaluating effectiveness of a method for treating gliomas, comprising: measuring the level of expression of at least one miRNA comprising hsa-miR-126, hsa-miR-15b, hsa-miR-16, hsa-miR-17, hsa-miR-20a, hsa-let7a, hsa-let 7f, hsa-let 7d, hsa-miR-374, hsa-miR-409, hsa-miR-134, hsa-miR-339, hsa miR-127, hsa-miR-151, hsa-miR-26b, hsa-miR-34b, hsa-miR-155, hsa-miR-210 or hsa-miR-10a in a biological sample from a patient subjected to glioma treatment, and optionally comparing the level of expression of the miRNAs in the biological sample from the patient, and respectively the level of expression of the miRNAs in a reference sample from a patient having glioblastoma and respectively the level of expression of the miRNA in a reference sample from a patient having oligodendroglioma.